Page 15 - 81_02
P. 15
residues as the cause of vulture population decline in Francisco Díaz-Fierros Viqueira
Pakistan. Nature 2004; 427: 630-633.
chromatography diode array detection. Jour. Chromatogr.
31. Sumpter JP. Pharmaceuticals in the Environment: 2009; 1216, 29: 5489-5496.
Moving from a Problem to a Solution. En: Kümmerer, K.
and Hempel, M. Eds. Green ans Sustainable Pharmacy. 43. Rosal R, Rodriguez A, Perdigon-Melón JA, Petre A.
Springer-Verlag. Berlin 2010. García-CalvoE, Gómez MJ, Agüera A y Fernández-Alba
AR.Ocurrence of emerging pollutants in urban wastewater
32. Solé M, López de Alda, MJ, Castillo M, Porte C, and their removal through biological treatment followed
Ladegaard-Pedersen K, Barceló D. Estrogenicity by ozonation. Water. Res. 2010; 44, 2: 578-588.
determination in sewage treatment plants and surface
waters fron Catalonian area (NE Spain). Environm. Sci. 44. Matamoros V, García J. y Bayona JM. Behaviour of
Technol. 2000; 34: 5076-5083. selected pharmaceuticals in subsurface flow constructed
wetlands: a pilot-scale study. Env. Sci. Tecnol. 2005;
33. Petrovic M., Solé M., López de Alda MJ., Barceló D. 39,14: 5449-5454.
Endocrine disruptors in sewage treatment plants, receiving
waters and sediments: Integration of chemical analysis and 45. Mendez-Arriaga F, Gimenez J y Esplugas S.
biological effects on feral carp. Environm. Toxicol. Photocatalytic degradation of non-steroidal
Chem.,2002; 21: 2146-2156. antiinflammatory drugs with TiO2 and simulated solar
irradiation. Water Res.2008; 42,3: 585-594.
34. Farré M, Ferrer I, Ginebreda A, Figueras M, Olivella
L., Tirapu Ll. Vilanova M. Barceló D. Determination of 46. Ventura F, Huerta-Fontenla M. y Galcerán MT.
drugs in surface water and wastewater samples by liquid Ocurrence and removal of pharmaceuticals and hormones
chromatography-mass spectrometry. Methods and through drinking water treatment. Water Res. 2011; 45,3:
prelimiray results incluiding toxicity studies with Vibrio 1432-1442.
fischeri. J. Choromatogr. A, 2001; 938: 187-197.
47. Nieto A, Borull F, Pocurull E. y Marcé RM. Ocurrence
35. Carballa M, Oimil F, Lema JM, Llompart M., Jarcia- of pharmaceuticals and hormones in sewage sludge. Env.
Jares C, Rodriguez I, Gomez, M. y Ternes T. Behaviour Toxicol. Chem. 2010; 29,7: 1448-1489.
of pharmaceuticals , cosmetics and hormones in a sewage
treatment plant. Water Res. 2004; 38: 2918-2926. 48. EMA. Environmental risk assessment for veterinary
medicinal products other than GMO contanining and
36. Carballa M, Oimil F y Lema JM. Removal of cosmetic inmunnological products (EMEA/CVMP/055/96) 1997.
ingrediants and pharmaceuticals in sewage primary
treatments. Water Res. 2005; 39: 4790-4796. 49.VICH. International Cooperation on Harmonisation of
Technical Requirements for Registration of Veterinary
37. Suárez S, Carballa M, Oimil F y Lema JM. How are Medicinal Products. Environmental Impact Assessment
pharmaceuticals and personal care products (PPCPs) (EIAs) for veterinary medicinal products (VMPs). Phase
removal from urban wasterwater? Rev. Environm. Sci. II. VICH GL 38. U.S. Dept. Health and Human Services
Biotechnol. 2008; 7: 125-138. 2006.
38.Santos JL, Aparicio I. y Alonso E . Ocurrence and risk 50. VICH. International Cooperation on Harmonisation of
assessment of pharmacutally active compounds in Technical Requirements for Registration of Veterinary
wasterwater treatment plants. A case study: Sevilla city Medicinal Products . Guidance for Industry. Studies to
(Spain). Environm. International. 2007; 33: 596-601. Evaluate the Safety of Residues of Veterinary Drugs:
General Approach to Testing. VICH GL 33. U.S. Health
39. Camacho-Muñoz D, Martin J, Santos JL, Aparicio I y and Human Services 2009.
Alonso E. Ocurrence, temporal evolution and risk
assessment of pharmaceutically active compounds in 51. European Medicines Agency (EMA). Revised
Doñana Park (Spain). Jour. Hazardous Materials, 2010; Guideline on Environmental Impact Assessment for
183: 602-608. Veterinary Pharmaceuticals in support of the VICH
Guidelines GL6 and GL38 (VICH-TGD),
40. Benitez FJ, Real FJ, Acero JL, y Roldan G. Removal (EMEA/CVPM/ERA/418282/2005-Rev.1. Londres, 1
of selected pharmaceuticals in waters by photochemical Nov., 2007.
processes. Jour. Chem. Tech. Biotecnl. 2009; 84,8: 1186-
1195. 52. EMA Guideline on the environmental risk assessment
of medicinal products (CHMP/SWP/00) 2006.
41. Ibañez M, Guerrero C, Sancho JV. y Hernández F.
Screening of antibiotics in surface and wastewaters 53. U.S. Dept. Health and Human Services. Guidance for
samples by ultra-high-pressure liquid chromatography Industry. 1998.
coupled to hybrid quadrupole time-of-flight mass
spectrometry. Jour. Chromatogr. 2009; 1216, 12: 2529- 54. Kümmerer K. (Eds.) Pharmaceuticals in the
2539. Environment. Sources, Fate, Effects and Risks.. Springer-
Verlag. Berlin 2nd ed. 2004, 3rd ed. 2008.
42. Gil García, MD, Cañada F, Calzoni, MJ, Vera-
Candioti L, Siano GG., Goicochea HC. y Mártinez-Galera 55. KNAPPE project. Knowledge and Need Assessment
M. . Chemometric tools improving the determination of on Pharmaceuticals Products in Environmental Waters.
anti-inflammatory and antiepileptic drugs in river and Final report. 2008.
wastewater by soild-phase microextraction and liquid
56. BIO Intelligence Service. Study on the Environmentl
98 risks of medicinal products. Executive Agency for Health
and Consumers. Paris 2013.
@Real Academia Nacional de Farmacia. Spain
